Search

Celgene Corp Combination Therapy Patent US12605372B2 Granted

The USPTO granted Patent US12605372B2 to Celgene Corporation on April 21, 2026. The patent covers methods of treating cancers by administering Compound A in combination with daratumumab, or Compound A with daratumumab and dexamethasone. The patent contains 19 claims and derives from Application No. 17983762, filed November 9, 2022.